Cristina Tănăseanu *, Monica Popescu *, Felicia Constantin *, Ștefăniță Tănăseanu **, Liliana Udma *, Sonia Preduma *, Alina Cojan *, Monica Neagu *
* Clinica Medicală, Spitalul “Sf. Pantelimon”, U.M.F. “Carol Davila”, București
** Clinica Medicală, Spitalul “N. Gh. Lupu”, U.M.F. “Carol Davila”, București
Abstract
We studied 63 patients with chronic heart failure moderate to severe, to asses the risks and the benefits of the anticoagulant treatment with low molecular weight heparins (LMWHs) – reviparine [Clivarin -Knoll) and nadroparine [Fraxiparine-Sanofi], in addition to the clinical study there were done “in vitro” studies regarding the state of activation of peripheral leucocytes in patients with CHF, and the effect of LMWHs on peripheral leukocytes in these patients. The investigation showed the presence of a systemic increase in polimorphonuclear neutrophils activity and a decrease in T-lymphocytes activity in patients with CHF and active coronary disease. The clinical results and the data obtained from “in vitro” studies revealed the beneficial effects of the anticoagulant therapy with Clivarin and Fraxiparine in patients with CHF. These LMWHs possess immunomodulatory properties, which are thought to complete their established antithrombotic activity.